The comparison of serial SPECT-CT imaging to estimate absorbed dose to the organ at risk from peptide receptor radionuclide therapy dosimetry

被引:0
|
作者
Bin Said, Mohamad Aminudin [1 ,2 ]
Razak, Hairil Rashmizal Bin Abdul [2 ]
Musarudin, Marianie [3 ]
机构
[1] Inst Kanser Negara, Dept Nucl Med, Putrajaya, Malaysia
[2] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Radiol, Serdang, Selangor, Malaysia
[3] Univ Sains Malaysia, Sch Hlth Sci, Hlth Campus, Kubang Kerian, Kelantan, Malaysia
来源
IRANIAN JOURNAL OF NUCLEAR MEDICINE | 2021年 / 29卷 / 01期
关键词
Lu-177-Dotatate; Dosimetry; SPECT-CT; 3D; KIDNEY; LU-177;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide such as Lu-177 label with a pharmaceutical agent useful to destroy the lesion. The amount of Lu-177 radioactivity administered to the patients is still not standardize and generally not more than 7.4 GBq per session due to the patient's safety issues. The first cycle of Lu-177 is an excellent technique to estimate radionuclide uptake for organs at risk. This study aims to simplify five SPECT-CT scanning points into less scanning points to estimate absorbed dose to the organ at risk. Methods: Ten patients who have neuroendocrine tumors enrolled in Lu-177-Dotatate therapy dosimetry. The serial SPECT-CT done after 2, 4, 24, 48 and 72 hours to acquired time disintegration for organ at risk. Partik's categorical grading criteria is relevantly used in this study to convert the numeric value of Lin's concordance coefficient into an ordinal scale. Results: Our current result demonstrated an excellent agreement between three and five scanning with LSA exponential fit method. These excellent results presented for kidney, liver and spleen. However, the bladder shows poor results due to the urinary system. Conclusion: Three data point of SPECT-CT images is the best option to estimate absorbed dose to the lesion and organ at risk for Lu-177-Dotatate dosimetry technique.
引用
收藏
页码:2 / 7
页数:6
相关论文
共 50 条
  • [41] Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
    Goodman, S.
    Smith, J.
    Kumar, Ravi A.
    Wyld, D.
    Burge, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 58 - 58
  • [42] A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours
    Marin, Gwennaelle
    Vanderlinden, Bruno
    Karfis, Ioannis
    Guiot, Thomas
    Wimana, Zena
    Reynaert, Nick
    Vandenberghe, Stefaan
    Flamen, Patrick
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2018, 56 : 41 - 49
  • [43] Effect of image registration on 3D absorbed dose calculations in 177Lu-DOTATOC peptide receptor radionuclide therapy
    Grassi, Elisa
    Fioroni, Federica
    Berenato, Salvatore
    Patterson, Nick
    Ferri, Valentina
    Braglia, Luca
    Filice, Angelina
    Versari, Annibale
    Iori, Mauro
    Spezi, Emiliano
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2018, 45 : 177 - 185
  • [44] Impact of kidneys absorbed dose assessment during177Lu-PRRT (peptide receptor radionuclide therapy) on patient management: examples from clinical experience
    Ferrari, M.
    Botta, F.
    Grana, C.
    Alio, D.
    Barone, A.
    Minischetti, G. Castiglione
    Papi, S.
    Clerici, I.
    Ceci, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S644 - S644
  • [45] Dual-tracer PET/CT imaging in response assessment to peptide receptor radionuclide therapy - a case report
    Prospero, I.
    Ferreira, G.
    Ferro, J. C.
    Barbosa, D.
    Silva, D. G.
    Fontao de Castro, S.
    Teixeira, J. P.
    Duarte, H.
    Lucena Sampaio, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S218 - S218
  • [46] A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
    Daphne M. V. Huizing
    Steffie M. B. Peters
    Michelle W. J. Versleijen
    Esther Martens
    Marcel Verheij
    Michiel Sinaasappel
    Marcel P. M. Stokkel
    Berlinda J. de Wit-van der Veen
    EJNMMI Physics, 7
  • [47] A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
    Huizing, Daphne M., V
    Peters, Steffie M. B.
    Versleijen, Michelle W. J.
    Martens, Esther
    Verheij, Marcel
    Sinaasappel, Michiel
    Stokkel, Marcel P. M.
    de Wit-van der Veen, Berlinda J.
    EJNMMI PHYSICS, 2020, 7 (01)
  • [48] Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
    Mileva, M.
    Marin, G.
    Levillain, H.
    van Bogaert, C.
    Critchi, G.
    Marin, C.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 153 - 153
  • [49] ASSESSMENT OF EFFECTIVE DOSE FROM CONE BEAM CT IMAGING IN SPECT/CT EXAMINATION IN COMPARISON WITH OTHER MODALITIES
    Tonkopi, Elena
    Ross, Andrew A.
    RADIATION PROTECTION DOSIMETRY, 2016, 172 (04) : 438 - 442
  • [50] Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin(R)) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
    Wahl, Richard L.
    Frey, Eric C.
    Jacene, Heather A.
    Kahl, Brad S.
    Piantadosi, Steven
    Bianco, Jesus A.
    Hammes, Richard J.
    Jung, Miah
    Kasecamp, Wayne
    He, Bin
    Sgouros, George
    Flinn, Ian W.
    Swinnen, Lode J.
    CANCERS, 2021, 13 (11)